|1.||Kinon, Bruce J: 2 articles (01/2013 - 06/2011)|
|2.||Millen, Brian A: 2 articles (01/2013 - 06/2011)|
|3.||Kollack-Walker, Sara: 2 articles (01/2013 - 06/2011)|
|4.||Jackson, Kimberley: 2 articles (02/2012 - 06/2011)|
|5.||Seeman, Philip: 2 articles (03/2009 - 03/2009)|
|6.||Schoepp, Darryle D: 2 articles (07/2008 - 07/2007)|
|7.||Johnson, Bryan G: 2 articles (07/2008 - 07/2007)|
|8.||Witcher, Jennifer W: 1 article (01/2015)|
|9.||Mitchell, Malcolm I: 1 article (01/2015)|
|10.||Cornelissen, Karen: 1 article (01/2015)|
|1.||Schizophrenia (Dementia Praecox)
07/01/2007 - "As glutamatergic dysfunction has been linked to the etiology of schizophrenia, clinical studies with more potent mGlu2/3 agonists, such as LY404039, may be useful to explore the validity of this hypothesis."
05/01/2011 - "Finally, using LY404039, a compound in development against schizophrenia, we have shown that the hyperactivity assay is sensitive to potential novel mechanisms of action. "
03/01/2009 - "However, a 2007 report found that the glutamate agonist LY404039 was effective in schizophrenia, suggesting a hypoglutamate state for the illness. "
09/01/2009 - "Importantly, clinical validation of the mechanism was achieved in a Phase II study in schizophrenia patients with mGluR2/3 agonist LY404039. "
06/01/2011 - "The primary objective of this study was to test the hypothesis that 1 or more dose levels of LY2140023 monohydrate, an oral prodrug of the potent metabotropic glutamate (mGlu) 2/3 receptor agonist LY404039, given to patients with schizophrenia for 4 weeks would demonstrate significantly greater efficacy than placebo. "
|2.||Glutamic Acid (Glutamate)
|3.||Excitatory Amino Acid Agonists
|7.||metabotropic glutamate receptor 2
|8.||Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)
|10.||Risperidone (Risperdal Consta)